MaxiVAXSA, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, announced today that it had been awarded a European Commission grant of €2,785,000, thanks to the Horizon 2020EIC Accelerator Programme.MaxiVAX was among 94 funded projects out of 2,015 applicants, thereby ranking among the top 4% of high-tech companies.
The company also reported the successful closing of a Series B 2 roundof CHF 5 million from new and existing investors, whose continuing support the company is particularly grateful.
The project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 880194.
MaxiVAX is a Swiss clinical-stage biotechnology company which, having completed a first-in-man Phase I clinical study, is now planning to perform several Phase II multicenter studies in different types of cancer.
First generation cancer immunotherapies are paving the way for MaxiVAX’s personalized immunotherapy.
A novel and proprietary way to reprogram and boost the patient’s own immune system for fighting cancer.
Rue de l'Athénée 24
+41 22 552 26 13